NOV 28 2026
PolyPid — D-PLEX100 $PYPD
for prevention of surgical site infection in abdominal colorectal surgery
Accepted JUL 29 2026.
Drug Watch — recent news on D-PLEX100
- PolyPid's D-PLEX100 NDA accepted with FDA Priority Review; PDUFA date 28 November 2026 - Dealroom.co
- PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review - Investing.com
- PolyPid, Azurity Sign US$330M Deal for D-PLEX100 - Streetwise Reports
- Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid - Yahoo Finance
- PolyPid's D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3 - Stock Titan
Sponsor Watch — recent news on PolyPid
- PolyPid Announces Participation in Upcoming Fall Investor Conferences
- PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
- Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid
- PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada